文献速递类风湿关节炎

类风湿关节炎口服与皮下甲氨蝶呤的有效性和耐受性比较

Effectiveness and tolerability of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

结果显示两组DAS28CRP变化无显著差异,口服组非劣于皮下组,且口服组不良事件累积发生率更低。

要点

  • 口服MTX在疾病活动度控制上非劣于皮下MTX
  • 口服组平均MTX剂量略低且不良事件累积发生率更低
  • 支持在HCQ联合和达标治疗背景下起始口服MTX

核心结论

  • 在真实世界RA患者中,起始口服MTX在疾病活动度控制方面非劣于皮下MTX。
  • 口服MTX的耐受性更好,支持起始口服MTX的策略。

研究设计与样本

  • 259例起始口服MTX,381例起始皮下MTX。
  • 主要结局为基线与3-6个月间DAS28CRP变化的组间差异优效性检验,非优效时进行非劣效性检验(非劣效界值0.6)。

主要发现

  • 校正混杂后ΔDAS28CRP组间差异为0.13(95%CI:-0.14,0.40),无显著差异,口服MTX策略非劣于皮下MTX。
  • 口服组平均MTX剂量略低[18.0(6.9)vs 19.9(8.2),P=0.002]。
  • 口服组不良事件累积发生率更低(41% vs 52%,P=0.005)。
  • 两组其他联合用药使用无差异。

关键数值与推荐

  • 非劣效界值为0.6。
  • 口服MTX非劣效于皮下MTX,至少在使用剂量达25 mg、背景为HCQ联合治疗和达标治疗策略时。

临床怎么用

  • 在真实临床实践中,可考虑起始口服MTX治疗RA,尤其在使用剂量不超过25 mg并联合HCQ及达标治疗策略时。
  • 口服MTX耐受性更好,可能有助于提高治疗依从性。

局限性

  • 本研究为回顾性队列研究,可能存在混杂偏倚。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to compare the effectiveness and tolerability between oral MTX and s.c. MTX in a large group of RA patients in a real-life setting. METHODS: In this retrospective cohort study, adult patients with clinical diagnosis of RA who started MTX treatment (monotherapy or combined with HCQ) started with either oral or s.c. MTX. The primary outcome was superiority testing of between group difference in change in DAS28CRP between baseline and 3-6 months, and subsequent non-inferiority (non-inferiority margin 0.6) testing analyses in case of non-superiority. Secondary outcomes included MTX dose, side effects, laboratory abnormalities and use of comedication. RESULTS: Six hundred and forty RA patients were included: 259 started with oral MTX and 381 with s.c. MTX. There was no significant difference in ΔDAS28CRP [after adjusting for confounding, 0.13 (95% CI: -0.14, 0.40)], and oral MTX strategy was non-inferior to s.c. The mean MTX dose was slightly lower for the oral strategy [18.0 (6.9) vs 19.9 (8.2), P = 0.002], which was accompanied by a lower cumulative incidence of adverse events (41% vs 52%, P = 0.005). No differences were seen in use of other comedication. CONCLUSION: Starting with oral MTX in RA in a real-life setting is non-inferior to a s.c. MTX treatment with regard to disease activity control, at least when used in dosages up to 25 mg and on a background of HCQ co-treatment and a treat-to-target approach. In addition, tolerability was better. This supports the strategy of starting with oral MTX.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Heuvelmans J, den Broeder N, van den Elsen GAH, et al. Effectiveness and tolerability of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis. Rheumatology (Oxford). 2021. PMID: 33788911. doi:10.1093/rheumatology/keab313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。